Frank M. Senecal

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

A Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia in Patients With Breast, Lung, or Gynecologic Cancer

Lee S. Schwartzberg, Lorrin Yee, Frank M. Senecal et al. · The Oncologist · 2004 · 104 citations · Full text

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

Harry D. Bear, Gong Tang, Priya Rastogi et al. · Journal of Clinical Oncology · 2011 · 39 citations

Surgical Oncology, Breast Oncology, Immunology +16

Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 μg Every 2 Weeks Versus Epoetin Alfa 40,000 U Weekly

Frank M. Senecal, Lorrin Yee, Nashat Gabrail et al. · Clinical Breast Cancer · 2005 · 26 citations

Breast Oncology, Oncology, Hematology +8

Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer

Lee S. Schwartzberg, Patrick Cobb, Frank M. Senecal et al. · The Breast · 2009 · 16 citations

Endocrine Oncology, Breast Oncology, Adjuvant Endocrine Therapy +8